- Prospectus filed pursuant to Rule 424(b)(3) (424B3)
10 April 2009 - 8:38PM
Edgar (US Regulatory)
|
Prospectus
Supplement No. 1
|
|
Filed
Pursuant to Rule 424(b)(3)
|
|
File
No. 333-155280
|
OPTIMIZERX
CORPORATION
407
Sixth Street
Rochester,
MI 48307
(248)
651-6558
Prospectus
Supplement No. 1
(to Final
Prospectus dated February 12, 2009)
This
Prospectus Supplement No. 1 supplements and amends the final prospectus dated
February 12, 2009 (the “Final Prospectus”), relating to the sale from time to
time of up to 2,230,000 shares of common stock by certain selling
stockholders.
On April
6, 2009, we filed with the U.S. Securities and Exchange Commission the attached
Form 8-K relating to the appointment of David Lester as our Director and Chief
Executive Officer.
This
Prospectus Supplement No. 1 should be read in conjunction with the Final
Prospectus and is qualified by reference to the Final Prospectus except to the
extent that the information in this Prospectus Supplement No. 1 supersedes the
information contained in the Final Prospectus.
Our
shares of common stock are quoted on the Pink Sheets and trade under the ticker
symbol “OPRX.” On April 2, 2009, the last reported sale price of our common
stock was $4.35 per share.
Investing
in our common stock involves a high degree of risk. See “Risk
Factors”
beginning
on page 7 of the Final Prospectus dated February 12, 2009.
Neither
the Securities and Exchange Commission nor any state securities commission has
approved or disapproved of these securities or determined if this Prospectus
Supplement No. 1 is truthful or complete. Any representation to the contrary is
a criminal offense.
The
date of this Prospectus Supplement No. 1 is April 6, 2009.
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
____________________
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported): April 6,
2009
OptimizeRx
Corporation
(Exact
name of registrant as specified in its charter)
Nevada
|
000-53605
|
26-1265381
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(I.R.S.
Employer Identification No.)
|
407 Sixth Street,
Rochester, MI
|
48307
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
248.651.6568
___________________________________________________
(Former
name or former address, if changed since last
report)
|
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
[
]
|
Written
communications pursuant to Rule 425 under the Securities Act (17CFR
230.425)
|
|
|
[
]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
|
[
]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
|
[
]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
SECTION
1 – Registrant’s Business and Operations
Item
1.01 Entry into a Material Definitive Agreement
The
information provided in Item 5.02 concerning the entry into a material
definitive agreement is incorporated by reference in this Item
1.01.
SECTION
5 – Corporate Governance and Management
Item
5.02
Departure
of Directors or Principal Officers; Election of Directors; Appointment of
Principal Officers
Effective
April 6, 2009, Mr. David Harrell resigned in all capacities as an officer of our
company. On April 6, 2009, the board of directors appointed Mr. David
Lester to act as our Chief Executive Officer and a member of our board of
directors.
David Lester
is a business
veteran whom has accumulated over thirty years of executive experience in the
areas of business, marketing, sales, operations, technology, and
leadership. Prior to accepting his new role with us, Mr. Lester
held the title of Director, Consumer & Industrial Products Marketing for
Deloitte LLP. During his tenure at Deloitte, he established Deloitte
as a leader through innovative programs and strategic
partnerships. Prior to Deloitte, he worked with Sun Microsystems as
Director, Industry Strategy & Marketing, and Manufacturing
Industries.
David
Lester has worked with Governor Tommy Thompson, former Secretary of Health &
Human Services, on health care reform and cost control; partnered with Governor
Tom Ridge, former head of Homeland Security on defending cyber security
initiatives; and as a active participant within the National Association of
Manufacturers and the Manufacturing Institute worked with former Michigan
Governor John Engler, now President of the National Association of
Manufacturers, on challenges inhibiting the competitiveness of
manufacturers like health care reform, trade policy, renewable energy, business
tax reform, and sustainability.
There are
no family relationships between Mr. Lester and any of our directors or executive
officers.
Aside
from the following, Mr. Lester has not had any material direct or indirect
interest in any of our transactions or proposed transactions over the last two
years.
On April
6, 2009, we entered into an employment agreement with Mr.
Lester. Under the agreement, we agreed to compensate Mr. Lester
$150,000 annually and we granted him options to purchase 500,000 shares of our
common stock, with 25% vesting immediately and 25% vesting after the completion
of each quarter of hire. Mr. Lester is also eligible for additional
quarterly and annual bonus compensation, stock options, and stock grants based
on performance metrics outlined by our board of directors. He is
entitled to vacation and sick days, and other benefits included in the
agreement.
A
copy of the employment agreement is attached hereto as Exhibit 10.1, and is
incorporated herein by reference. The foregoing description of the employment
agreement is qualified in its entirety by reference to the full text
thereto.
SECTION
8 – Other Events
Item
8.01 Other Events
On April
6, 2009, we issued a press release concerning the appointment of Mr.
Lester. The press release is attached hereto as Exhibit
99.1.
SECTION
9 – Financial Statements and Exhibits
Item
9.01 Financial Statements and Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
OptimizeRx
Corporation
/s/
David Lester
David
Lester
Chief
Executive Officer
Date:
April 8, 2009
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jul 2023 bis Jul 2024